These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38050024)

  • 21. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma.
    Narita M; Hatano E; Arizono S; Miyagawa-Hayashino A; Isoda H; Kitamura K; Taura K; Yasuchika K; Nitta T; Ikai I; Uemoto S
    J Gastroenterol; 2009; 44(7):793-8. PubMed ID: 19404564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
    Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
    AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images.
    Yoneda N; Matsui O; Kitao A; Kita R; Kozaka K; Koda W; Kobayashi S; Gabata T; Ikeda H; Sato Y; Nakanuma Y
    Jpn J Radiol; 2012 Jul; 30(6):499-508. PubMed ID: 22618456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of discrepancy of the central scar-like structure between dynamic CT and gadoxetate disodium-enhanced MRI in differentiation of focal nodular hyperplasia and hepatocellular adenoma.
    Park HJ; Byun JH; Kang JH; Kang HJ; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur J Radiol; 2021 Jun; 139():109730. PubMed ID: 33930719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma.
    Suh CH; Kim KW; Park SH; Shin S; Ahn J; Pyo J; Shinagare AB; Krajewski KM; Ramaiya NH
    Eur Radiol; 2018 Jan; 28(1):214-225. PubMed ID: 28726119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
    Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
    Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
    Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
    Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
    Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
    Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison.
    Cannella R; Brancatelli G; Rangaswamy B; Minervini MI; Borhani AA; Furlan A
    Eur J Radiol; 2019 Oct; 119():108633. PubMed ID: 31437747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia.
    Bröker MEE; Taimr P; de Vries M; Braun LMM; de Man RA; Ijzermans JNM; Dwarkasing RS
    AJR Am J Roentgenol; 2020 Jan; 214(1):81-89. PubMed ID: 31573852
    [No Abstract]   [Full Text] [Related]  

  • 32. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma.
    Ueno A; Masugi Y; Yamazaki K; Komuta M; Effendi K; Tanami Y; Tsujikawa H; Tanimoto A; Okuda S; Itano O; Kitagawa Y; Kuribayashi S; Sakamoto M
    J Hepatol; 2014 Nov; 61(5):1080-7. PubMed ID: 24946283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
    Auer TA; Fehrenbach U; Grieser C; Penzkofer T; Geisel D; Schmelzle M; Müller T; Bläker H; Seehofer D; Denecke T
    Eur Radiol; 2020 Jun; 30(6):3497-3506. PubMed ID: 32086574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging.
    Ba-Ssalamah A; Antunes C; Feier D; Bastati N; Hodge JC; Stift J; Cipriano MA; Wrba F; Trauner M; Herold CJ; Caseiro-Alves F
    Radiology; 2015 Oct; 277(1):104-13. PubMed ID: 25985059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
    Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
    J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI.
    Zhou X; Long L; Mo Z; Li Y
    Cancer Manag Res; 2021; 13():1169-1177. PubMed ID: 33603462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
    Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
    Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background.
    Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Inoue D; Ogi T; Yoshida K; Gabata T
    Eur Radiol; 2020 Jun; 30(6):3438-3447. PubMed ID: 32064560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma.
    van den Esschert JW; van Gulik TM; Phoa SS
    Dig Surg; 2010; 27(1):46-55. PubMed ID: 20357451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.